Kelun-Biotech to Showcase Groundbreaking Studies on NSCLC Treatments at ASCO 2026

The upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place in Chicago from May 29 to June 2, where Kelun-Biotech will present its pivotal studies focusing on treatments for non-small cell lung cancer (NSCLC). This event gathers worldwide oncology professionals and researchers to discuss the latest findings and advancements in cancer treatment.

Kelun-Biotech, a leading biopharmaceutical firm based in Chengdu, China, has announced two critical registrational studies will be highlighted in an oral presentation session. The first study involves sacituzumab tirumotecan (sac-TMT), a novel TROP2-directed antibody-drug conjugate, combined with pembrolizumab as a potential first-line treatment for patients with advanced PD-L1 positive NSCLC. This study, known as the OptiTROP-Lung05, explored the effectiveness of sac-TMT plus pembrolizumab compared to pembrolizumab alone. Key outcomes demonstrated a significant improvement in progression-free survival (PFS) for the combination therapy, showcasing substantial response rates which indicate a strong potential for enhanced patient outcomes.

In the OptiTROP-Lung05 study, a total of 413 patients were enrolled, all suffering from untreated locally advanced or metastatic NSCLC, characterized by their PD-L1 positivity. With a median follow-up period of 10.5 months, findings revealed a remarkable enhancement in PFS among those receiving sac-TMT with pembrolizumab compared to the control. The results showed a median PFS that was not yet reached for the combination therapy versus 5.7 months for pembrolizumab alone, indicating a promising direction in NSCLC treatment protocols.

Additionally, the study indicated a higher objective response rate (ORR) of 70.2% for the combination therapy in contrast to 42% for pembrolizumab alone. Although the overall survival data trend remains immature, preliminary insights indicated benefits across numerous patient subgroups, reinforcing the potential of this combination regimen in the NSCLC landscape.

The second significant study pertains to lunbotinib fumarate, a next-generation selective RET inhibitor, which will also be presented at ASCO. This pivotal Phase II study enrolled 163 patients, divided into pre-treated and treatment-naïve groups, comprising patients with RET-fusion positive NSCLC. The presentation will highlight the efficacy and safety of lunbotinib, which has already shown promising outcomes. Preliminary data indicates a confirmed ORR of 87.1% in pre-treated patients and 81.3% in treatment-naïve patients. Additionally, the study documented median PFS rates reflecting robust efficacy, suggesting lunbotinib may represent a vital therapeutic option for patients grappling with RET-altered lung cancer.

As this annual meeting approaches, the pharmaceutical community eagerly anticipates the insights these studies will bring forward. Healthcare professionals are hopeful that the results introduced at the ASCO 2026 will pave the way for novel therapeutic strategies that could fundamentally change the clinical management of NSCLC.

Furthermore, both studies underscore Kelun-Biotech’s dedication to advancing cancer treatment options within the global healthcare framework. By focusing on unmet medical needs through innovative drug solutions, Kelun-Biotech is positioned at the forefront of oncology research and development. The company continues to work intensively, expecting a supplemental New Drug Application review regarding sac-TMT in combination with pembrolizumab, which could catalyze new standards in first-line treatment protocols in NSCLC.

In conclusion, the 2026 ASCO Annual Meeting will showcase crucial research from Kelun-Biotech, embodying a step forward in the battle against lung cancer with the introduction of innovative therapies poised to significantly enhance patient care outcomes.